Pharmacokinetics of wogonin-aloperine cocrystal in rats
10.16438/j.0513-4870.2024-0351
- VernacularTitle:汉黄芩素-苦豆碱共晶在大鼠体内的药代动力学研究
- Author:
Zhong-shui XIE
;
Chun-xue JIA
;
Yu-lu LIANG
;
Xiao-jun ZHAO
;
Bin-ran LI
;
Jing-zhong HAN
;
Hong-juan WANG
;
Jian-mei HUANG
- Publication Type:Research Article
- Keywords:
ogonin;
aloperine;
pharmaceutical cocrystal;
pharmacokinetics;
bioavailability
- From:
Acta Pharmaceutica Sinica
2024;59(9):2606-2611
- CountryChina
- Language:Chinese
-
Abstract:
Pharmaceutical cocrystals is an advanced technology to improve the physicochemical and biological properties of drugs. However, there are few studies on the in vivo metabolism of pharmaceutical cocrystals. In this study, the pharmacokinetics of wogonin cocrystal in normal rats was further studied on the basis of the previous preparation of wogonin-aloperine cocrystal. Firstly, an ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method was established for simultaneous determination of wogonin and its metabolite wogonoside in rat plasma, and to investigate the methodology. The method was applied to the pharmacokinetic study of wogonin-aloperine cocrystal (Wog-Alop) in rats. The results showed that wogonin and its metabolite wogonoside had a good linear relationship in the range of 1-800 ng·mL-1, and the precision, accuracy, matrix effect and stability in this range met the requirements of biological analysis. Compared with direct administration of wogonin, the Cmax of wogonin and its metabolite in rats increased to 7.44-fold and 9.15-fold, AUC0-t increased to 1.67-fold and 3.72-fold, and oral bioavailability of wogonin increased to 187.66% after cocrystal administration. Wog-Alop cocrystal can significantly improve the Cmax, AUC, and oral bioavailability of wogonin and its metabolite, which provides a new perspective for the clinical application of wogonin. This study was approved by the Experimental Animal Ethics Review Committee of Beijing University of Chinese Medicine (approval number: BUCM-2023032307-1148).
